Istanbul (AFP) | 05/07/2025 - 08:45:32 | Turkey arrests three more opposition mayors: media
Hanoi (AFP) | 05/07/2025 - 08:27:36 | Vietnam posts 7.52% GDP growth in first half of 2025: statistics office
Hanoi (AFP) | 05/07/2025 - 08:23:00 | Vietnam posts 7.52% GDP growth in Q1: statistics office
Morristown (AFP) | 05/07/2025 - 06:08:41 | Trump says 'very unhappy' after Ukraine call with Putin
Morristown (AFP) | 05/07/2025 - 05:52:29 | Trump says 'could be' Gaza deal by next week
Morristown (AFP) | 05/07/2025 - 05:42:40 | Trump says 'probably 12' tariff letters being sent out Monday
Washington (AFP) | 05/07/2025 - 05:20:03 | Trump says 'shocking' Texas floods are 'terrible'
Washington (AFP) | 05/07/2025 - 04:50:56 | Texas flash flood death toll rises to 24: county official
Washington (AFP) | 04/07/2025 - 23:55:59 | Trump signs flagship US tax and spending bill into law
Gaza City (AFP) | 04/07/2025 - 23:16:11 | Islamic Jihad says supports Gaza ceasefire talks, demands 'guarantees'
AFP has the largest network in the world of expert journalists in charge of digital investigations. AFP’s fact-check service is covering 36 countries. In Asia alone, 11 countries and territories in five languages, including English, Thai, Bahasa Indonesia, Bahasa Malay and Burmese. Burmese is the 14th language to be added to the AFP Fact Check website.
Incyte (Nasdaq:INCY) today announced that primary results from the Phase 3 POD1UM-303/InterAACT 2 trial of retifanlimab (Zynyz®), a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1), in combination with carboplatin and paclitaxel (platinum-based chemotherapy) in adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal cancer (SCAC) who have not been previously treated with systemic chemotherapy, were published in The Lancet.1 ...
